Senesco Logo
Home About Us News and Media Our Technologies Clinical Development Commercialization Investor Relations Contact Us
  Senesco is a therapeutics company employing its strong proprietary platforms in gene regulation and antibody engineering. The Company's lead therapeutic candidate SNS01-T incorporates recent developments in siRNA, gene therapy and nanotechnology. Senesco is building its portfolio with other applications for SNS01-T in cancer and inflammation, as well as several monoclonal antibody therapeutic candidates.
  Clinical Trials  
  Senesco is sponsoring a Phase 1b/2a clinical trial of SNS01-T for patients with multiple myeloma who have relapsed from, or failed to respond to, at least two previous treatment regimens. For contact information, please visit the study page on

Senesco Announces New CEO
Senesco Presents Company Update at 2014 BIO International Convention
Senesco to Update on R&D Plans at BIO
facebook twitter youtube google+ linkedin